The goal of this proposal is to uncover the molecular mechanisms by which the Fbw7 tumor suppressor is implicated in cellular senescence. The long-term goals of my career are to apply the insight of molecular and cellular biology to understand the physiological significance of protein degradation machinery that is important in the development of human malignancies and aging-associated disorders. Fbw7 is a substrate recognition subunit of the E3 ubiquitin ligase complex SCFFbw7, which is well known to target numerous cell cycle positive regulators for proteasome-dependent degradation. Recent intensive studies elucidated a crucial tumor suppressor function for Fbw7. However, the molecular mechanism by which Fbw7 is implicated in cellular senescence is currently unknown. Our preliminary data showed that Fbw7 negatively regulates the stability of Raptor and Rictor, the essential accessory proteins of the mTOR complexes (mTORC). The mTOR pathway plays a pivotal role in sensing nutrition and energy in cells. Interestingly, recent studies revealed that mTOR signaling also negatively regulates longevity across species (from yeasts to mice). However, the upstream regulatory pathways governing mTOR activity during the aging process remain largely unknown. We hypothesize that Fbw7 is an upstream negative regulator of the mTOR signaling pathway through which Fbw7 plays an important role in regulating cellular senescence. In this proposal, we plan to: 1) Determine the physiological significance of SCFFbw7 during senescence, 2) Determine the role of SCFFbw7 in modulating cellular senescence via regulation of Raptor and Rictor protein stability, 3) Determine whether regulation of Raptor and Rictor by Fbw7 has a physiological role in controlling aging in hematopoietic stem cells (HSCs). This K01 award will provide protected time for me to pursue the hypotheses of this proposal, obtain new skill sets to execute experiments and solve problems. In addition, the award will also allow me to focus my efforts on independently conducting basic and translational research, and training of future young scientists. Should I receive this award, I will pursue this research in Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, where authorities in the fields of PI3 kinase signaling and cellular senescence locate. The outcome of the proposed studies will help elucidate whether Fbw7 can directly regular aging in vivo, and whether loss of Fbw7 function causes cellular senescence of HSCs via up-regulation of the mTOR pathway, which may contribute to the pathogenesis of leukemia in the elderly population. Importantly, this study suggests that loss of Fbw7 could be a conceivable biomarker for age-related hematological disorders and hence sensitivity to the mTOR specific inhibitors. We expect this will provide evidence toward the rationale for using mTOR pharmacological intervention in personalized medicine for age-related diseases.

Public Health Relevance

Aging of hematopoietic stem cells is considered a risk factor for leukemia development in elderly people. This proposal focuses on the molecular mechanisms by which the Fbw7 tumor suppressor participates in aging of hematopoietic stem cells by negatively regulating the mTOR pathway. Therefore, this study would impact the field of clinical hematology in aging and provide a new avenue of pharmacological intervention to treat age- related hematopoietic defects.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
1K01AG041218-01
Application #
8226041
Study Section
National Institute on Aging Initial Review Group (NIA)
Program Officer
Velazquez, Jose M
Project Start
2011-09-30
Project End
2016-08-31
Budget Start
2011-09-30
Budget End
2012-08-31
Support Year
1
Fiscal Year
2011
Total Cost
$124,146
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Shimizu, Kouhei; Fukushima, Hidefumi; Ogura, Kohei et al. (2017) The SCF?-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis. Sci Signal 10:
Nihira, Naoe T; Ogura, Kohei; Shimizu, Kouhei et al. (2017) Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function. Sci Signal 10:
Wan, Lixin; Chen, Ming; Cao, Juxiang et al. (2017) The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. Cancer Discov 7:424-441
Takada, Mamoru; Zhuang, Ming; Inuzuka, Hiroyuki et al. (2017) EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor. Oncotarget 8:6787-6795
Nagashima, Katsuyuki; Fukushima, Hidefumi; Shimizu, Kouhei et al. (2017) Nutrient-induced FNIP degradation by SCF?-TRCP regulates FLCN complex localization and promotes renal cancer progression. Oncotarget 8:9947-9960
Liu, Lijun; Michowski, Wojciech; Inuzuka, Hiroyuki et al. (2017) G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells. Nat Cell Biol 19:177-188
Hong, Xuehui; Liu, Wenyu; Song, Ruipeng et al. (2016) SOX9 is targeted for proteasomal degradation by the E3 ligase FBW7 in response to DNA damage. Nucleic Acids Res 44:8855-8869
Guo, Jianping; Chakraborty, Abhishek A; Liu, Pengda et al. (2016) pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Science 353:929-32
Li, Xiaoning; Dai, Xiangpeng; Wan, Lixin et al. (2016) Smurf1 regulation of DAB2IP controls cell proliferation and migration. Oncotarget 7:26057-69
Gan, Wenjian; Dai, Xiangpeng; Lunardi, Andrea et al. (2015) SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. Mol Cell 59:917-30

Showing the most recent 10 out of 44 publications